VP & Head, Collaborate2Cure Hub, US, BD&L
Imran is an intrapreneur driving external innovation with entrepreneurs. He possesses 25 years of business development & licensing, strategy, economic development, and technology transfer experience. Currently, Imran is Vice President and Head of Collaborate to Cure Hub-US within Business Development & Licensing at Bayer Pharmaceuticals; he is responsible for forging new business relationships with academia, biotech and venture capital for early & late stage access to technologies and assets.
Prior to Bayer, Imran worked for Boehringer Ingelheim in BD&L leading scouting and evaluation primarily in Boston & San Diego. Imran received Boehringer Ingelheim’s distinguished President’s Award within two years of joining BI. Imran possesses extensive experience covering strategy, business development, alliance management, partnering and licensing in diagnostics, personalized medicine, therapeutics, and technology platforms. He holds a proven track record at other blue-chip organizations like Genzyme Genetics (now LabCorp), Millennium Pharmaceuticals (Takeda), Dana Farber Cancer Center and Mayo Clinic. In the diversity of his experiences, Imran was also the Chief Business Officer for Massbio, where he led the successful turn-around of Massbio, making it the most successful biotechnology state trade-association in the country; at Massbio, he launched several ground breaking mentoring and partnering programs that were later adopted by other state trade associations.
Imran is passionate about ecosystem development and new company creation; towards that, he founded many innovative programs centered on life-science mentoring and partnering starting at Massbio, followed by Boehringer Ingelheim and now at Bayer. Through his various programs, Imran has coached over 300 early-stage companies over the past decade.